MYC and diffuse large B-cell lymphoma: Twenty-four out of 92 (26.1%) of the MYC- DLBCL patients in this matched subset were I-PET-positive, whereas 17 out of 92 (18.5%) of the MYC- DLBCL patients were EoT-PET-positive (Table 2).